Reata - RETA Net earnings per share growth forecast for next year

Corporate company logo of Reata Pharmaceuticals (RETA)

Reata Pharmaceuticals (RETA) is developing a biopharmaceutical network to combat rare neurodegenerative pathologies, leveraging the patent protection of Skyclarys. The consensus earnings per share (EPS) forecast vector demonstrates the impact of tight monetary policy on multiples, while the -2.40 level records fresh values. Revenues are constrained by insurance reimbursement complexities and marketing expenses. Consequently, the company is implementing an unrivaled therapy method for Friedreich's ataxia.

Reata (RETA): Net earnings per share growth forecast for next year from 07/04/2022 to 10/07/2023

Summary analytical data breakdowns for Reata (RETA)

Fundamental company analysis:RETA, Reata Pharmaceuticals
Finished products of Reata Pharmaceuticals Inc

Reata Pharmaceuticals (RETA) maintains exceptional pricing power due to its monopoly status in Friedreich's ataxia therapy, which is directly reflected in analysts' valuations of n+1 net profit dynamics. This indicator measures the expected percentage growth in earnings per share, allowing investors to assess the sustainability of expansion rates and promptly identify risks of a slowdown in the business's fundamental growth.

Competitor analysis for Reata Pharmaceuticals

Net earnings per share growth forecast for next year Jazz Pharmaceuticals|CYTK: Expected earnings per share trend next year|Net earnings per share growth forecast for next year PTC Bio (PTCT)|SRRK - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Centessa Pharmaceuticals PLC CNTA|Dyne Pharma (DYN) - Expected net earnings per share growth next year|EWTX - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Rapport Therapeutics, Inc.|ALMS: Earnings growth forecast for next year|Net earnings per one share growth forecast for next year Kempharm ZVRA|Expected earnings per share growth for next year CTNM|Expected net earnings per share growth next year Larimar Corp LRMR|Earnings growth forecast for next year CAPR|TRDA - Expected net earnings per share growth next year|Earnings growth forecast for next year PTHS (Channel Therapeutics Corp)|MediciNova Corp (MNOV) - Expected net earnings per share growth next year|Serina Pharma - Earnings growth forecast for next year|Expected net earnings per share growth next year BioXcel Therapeutics|PMN: Earnings growth forecast for next year|Expected earnings per share growth for next year Apimeds Pharmaceuticals, Inc.|Expected earnings per share growth for next year AEON|NLS Pharmaceutics AG - Net earnings per share change forecast for next year|Net earnings per share growth forecast for next year Bionomics Ltd. (BNOX)|HUGE (FSD Pharma Inc.) - Expected earnings per share trend next year